Stockreport

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being...

Actinium Pharmaceuticals, Inc. (Delaware)  (ATNM) 
NASDAQ:AMEX Investor Relations: ir.actiniumpharma.com
PDF /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced compelling p [Read more]